The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Cholinergic deafferentation of the rabbit cortex: a new animal model of Aβ deposition
Abstract
Brain deposition of the amyloid beta-peptide (Abeta) is a critical step in the pathogenesis of Alzheimer's disease (AD) and human cerebral amyloid angiopathy (CAA). A small fraction of AD and CAA cases are caused by gene mutations leading to increased production and deposition of Abeta, but for the majority, there is no known direct genetic cause. We have hypothesized that Abeta deposition in these sporadic cases occurs as a result of cortical cholinergic deafferentation. Here we show that cortical cholinergic deafferentation, induced in rabbits by a selective immunotoxin, leads to Abeta deposition in cerebral blood vessels and perivascular neuropil. Biochemical measurements confirmed that lesioned animals had 2.5- and 8-fold elevations of cortical Abeta40 and Abeta42, respectively. Cholinergic deafferentation may be one factor that can contribute to Abeta deposition.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The mechanism by which anticholinergic medications might contribute to dementia risk is biologically plausible.
“The mechanism by which anticholinergic medications might contribute to dementia risk has not been elucidated; however, a few lines of evidence suggest that it is biologically plausible.”
From Cumulative Use of Strong Anticholinergics and Incident Dementia: A Prospective Cohort Study (2015) · cites this paper as [39]
In animal models, reduced cholinergic transmission via atropine or cortical cholinergic denervation increased amyloid beta concentrations.
“Moreover, in animal models, reduced cholinergic transmission via atropine or cortical cholinergic denervation increased amyloid beta concentrations.38-40”
From Cumulative Use of Strong Anticholinergics and Incident Dementia: A Prospective Cohort Study (2015) · cites this paper as [39]
Citations
Cites
Genetics of Alzheimer's disease
Hutton, M., Pérez-Tur, J., & Hardy, J. (1998) · Essays in Biochemistry · doi:10.1042/bse0330117 · Cited by 88
Flagged first, then by citations
Research works printed but not linked: 18
- Beach, 1987, Perfusion-fixation of the human brain for immunohistochemistry: comparison with immersion-fixation, J. Neurosci. Meth., 19, 183, 10.1016/S0165-0270(87)80001-8 · DOI
- Calhoun, 1999, Neuronal overexpression of mutant amyloid precursor protein results in prominent deposition of cerebrovascular amyloid, Proc. Natl. Acad. Sci. USA, 96, 14088, 10.1073/pnas.96.24.14088 · DOI · Paper page
- Fine, 1997, Learning impairments following injection of a selective cholinergic immunotoxin, ME20.4 IgG-saporin, into the basal nucleus of Meynert in monkeys, Neuroscience, 81, 331, 10.1016/S0306-4522(97)00208-X · DOI
- Fonnum, 1969, Radiochemical micro assays for the determination of choline acetyltransferase and acetylcholinesterase activities, Biochem. J., 115, 465, 10.1042/bj1150465 · DOI
- Funato, 1998, Quantitation of amyloid β-protein (A beta) in the cortex during aging and in Alzheimer's disease, Am. J. Pathol., 152, 1633
- Horiguchi, 1989, Distribution, ultrastructural localization, and ontogeny of the core protein of a heparan sulfate proteoglycan in human skin and other basement membranes, J. Histochem. Cytochem., 37, 961, 10.1177/37.7.2659664 · DOI
- Johnstone, 1991, Conservation of the sequence of the Alzheimer's disease amyloid peptide in dog, polar bear and five other mammals by cross-species polymerase chain reaction analysis, Brain Res., 10, 299, 10.1016/0169-328X(91)90088-F · DOI
- Mehta, 1998, Increased plasma amyloid β protein 1–42 levels in Down syndrome, Neurosci. Lett., 241, 13, 10.1016/S0304-3940(97)00966-X · DOI · Paper page
- Nitsch, 1992, Release of Alzheimer amyloid precursor derivatives stimulated by activation of muscarinic acetylcholine receptors, Science, 258, 304, 10.1126/science.1411529 · DOI · Paper page
- Perry, 1992, Convergent cholinergic activities in aging and Alzheimer's disease, Neurobiol. Aging, 13, 393, 10.1016/0197-4580(92)90113-C · DOI
- Raby, 1998, Traumatic brain injury increases β-amyloid peptide 1–42 in cerebrospinal fluid, J. Neurochem., 71, 2505, 10.1046/j.1471-4159.1998.71062505.x · DOI
- Rossner, 1997, In vivo regulation of amyloid precursor protein secretion in rat neocortex by cholinergic activity, Eur. J. Neurosci., 9, 2125, 10.1111/j.1460-9568.1997.tb01379.x · DOI
- Savage, 1998, Turnover of amyloid β-protein in mouse brain and acute reduction of its level by phorbol ester, J. Neurosci., 18, 1743, 10.1523/JNEUROSCI.18-05-01743.1998 · DOI · Paper page
- Wallace, 1993, Amyloid precursor protein in the cerebral cortex is rapidly and persistently induced by loss of subcortical innervation, Proc. Natl. Acad. Sci. USA, 90, 8712, 10.1073/pnas.90.18.8712 · DOI
- Weller, 1998, Cerebral amyloid angiopathy: amyloid β accumulates in putative interstitial fluid drainage pathways in Alzheimer's disease, Am. J. Pathol., 153, 725, 10.1016/S0002-9440(10)65616-7 · DOI · Paper page
- Wiley, 1991, Immunolesioning: selective destruction of neurons using immunotoxin to rat NGF receptor, Brain Res., 562, 149, 10.1016/0006-8993(91)91199-B · DOI
- Wolf, 1995, Muscarinic regulation of Alzheimer's disease amyloid precursor protein secretion and amyloid β-protein production in human neuronal NT2N cells, J. Biol. Chem., 270, 4916, 10.1074/jbc.270.9.4916 · DOI
- Woodruff-Pak, 1996, The older rabbit as an animal model: implications for Alzheimer's disease, Neurobiol. Aging, 17, 283, 10.1016/0197-4580(95)02064-0 · DOI
Cited by
Sorted by citations
Cumulative Use of Strong Anticholinergics and Incident Dementia: A Prospective Cohort Study
Gray, S. L., Anderson, M. L., Dublin, S., Hanlon, J. T., Hubbard, R., Walker, R., Yu, O., Crane, P. K., & Larson, E. B. (2015) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2014.7663 · Cited by 1,111
The movers and shapers in immune privilege of the CNS
Engelhardt, B., Vajkoczy, P., & Weller, R. O. (2017) · Nature Immunology · doi:10.1038/ni.3666 · Cited by 893
Lymphatic drainage of the brain and the pathophysiology of neurological disease
Weller, R. O., Djuanda, E., Yow, H.-Y., & Carare, R. O. (2009) · Acta Neuropathologica · doi:10.1007/s00401-008-0457-0 · Cited by 488
Weller, R. O., Boche, D., & Nicoll, J. A. R. (2009) · Acta Neuropathologica · doi:10.1007/s00401-009-0498-z · Cited by 297
Carare, R. O., Hawkes, C. A., Jeffrey, M., Kalaria, R. N., & Weller, R. O. (2013) · Neuropathology and Applied Neurobiology · doi:10.1111/nan.12042 · Cited by 207
Cholinergic Changes in the APP23 Transgenic Mouse Model of Cerebral Amyloidosis
Boncristiano, S., Calhoun, M. E., Kelly, P. H., Pfeifer, M., Bondolfi, L., Stalder, M., Phinney, A. L., Abramowski, D., Sturchler-Pierrat, C., Enz, A., et al. (2002) · The Journal of Neuroscience · doi:10.1523/jneurosci.22-08-03234.2002 · Cited by 160
Potter, P. E., Rauschkolb, P. K., Pandya, Y., Sue, L. I., Sabbagh, M. N., Walker, D. G., & Beach, T. G. (2011) · Acta Neuropathologica · doi:10.1007/s00401-011-0831-1 · Cited by 94
Self-citation(2012) · Progress in Molecular Biology and Translational Science · doi:10.1016/b978-0-12-385883-2.00006-0 · Cited by 84
Metadata
- Authors
- Beach, T. G., Potter, P. E., Kuo, Y.-M., Emmerling, M. R., Durham, R. A., Webster, S. D., Walker, D. G., Sue, L. I., Scott, S., Layne, K. J., & Roher, A. E.
- Affiliations
- Banner Sun Health Research Institute (US)
- Midwestern University (US)
- University of California, Irvine (US)
- Corresponding author
- Beach, Thomas G
- Venue
- Neuroscience Letters
- Publisher
- Elsevier BV
- Published
- 2000-03
- Volume
- 283
- Issue
- 1
- Pages
- 9-12
- ISSN
- 0304-3940 (ISSN-L)
- OpenAlex
- W2083657833
- Cited by
- 71
- References
- 1
- Citations by year
- 2026: 2 · 2025: 2 · 2024: 4 · 2023: 2 · 2022: 1 · 2021: 5 · 2019: 2 · 2018: 2 · 2017: 2 · 2015: 2 · 2014: 1 · 2013: 1 · 2012: 3
- FWCI
- 1.98
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Neuroscience Letters (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institutes of Health (R03AG017289)
- National Institute on Aging (R01AG011925)
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Life Sciences › Neuroscience › Neurology › Neuroinflammation and Neurodegeneration Mechanisms
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Keywords
- cholinergic deafferentation, amyloid-beta deposition, Alzheimer's disease, cerebral amyloid angiopathy, Aβ40, amyloid-beta 42, cerebral vasculature, rabbit model, cortical cholinergic neurons
- MeSH terms
- Alzheimer Disease, Animals, Immunotoxins, Cerebral Cortex, Choline O-Acetyltransferase, Cholinergic Fibers, Denervation, Disease Models, Animal, Nerve Degeneration, Neurons, Neurotoxins, Rabbits, Amyloid beta-Peptides, Cerebral Amyloid Angiopathy, Basal Nucleus of Meynert
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
